Sigyn Therapeutics (SIGY) FCF Margin (2017 - 2020)
Sigyn Therapeutics (SIGY) posted FCF Margin of 5267.79% for Q3 2020, up 81.24% sequentially from 28075.53% in Q1 2020, and down 511583.0% YoY from N/an in Q4 2019.
Sigyn Therapeutics (SIGY) FCF Margin (2017 - 2020) Analysis & Trends
Sigyn Therapeutics has reported FCF Margin for 4 years, with the latest figure at 5267.79% in Q3 2020.
- Quarterly FCF Margin fell 511583.0% year-over-year to 5267.79% in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 5832.07% (down 575710.0% YoY) and the FY2019 annual result came in at 100.25%, up 91944.0% from the prior year.
- FCF Margin rose to 5267.79% in Q3 2020 per SIGY's latest filing, from 28075.53% in the prior quarter.
- Over five years, FCF Margin peaked at 33.82% in Q3 2018 and troughed at 1023100.0% in Q4 2018.
- A 4-year average of 75630.2% and a median of 132.39% in 2019 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2018 and 2019: FCF Margin plunged 102312375 bps in 2018, then jumped 102253791 bps in 2019.
- Over 4 years, FCF Margin stood at 23.75% in 2017, then slumped by 4308636 bps to 1023100.0% in 2018, then jumped by 100 bps to 562.09% in 2019, then tumbled by 837 bps to 5267.79% in 2020.
- According to Business Quant data, FCF Margin over the past three periods registered 5267.79%, 28075.53%, and 562.09% for Q3 2020, Q1 2020, and Q4 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 70.82% |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -5,267.79% |
| Mar 31, 2020 | -28,075.53% |
| Dec 31, 2019 | -562.09% |
| Sep 30, 2019 | -151.96% |
| Jun 30, 2019 | 12.34% |
| Mar 31, 2019 | -175.27% |
| Dec 31, 2018 | -1,023,100.00% |
| Sep 30, 2018 | 33.82% |
| Jun 30, 2018 | -112.81% |
| Mar 31, 2018 | -1,390.30% |
| Dec 31, 2017 | 23.75% |
| Sep 30, 2017 | 0.82% |
| Jun 30, 2017 | -17.49% |
| Mar 31, 2017 | -40.32% |